SD-RAVEN-INDUSTRIES
15.6.2021 15:17:10 CEST | Business Wire | Press release
Raven Industries, Inc. (the Company; NASDAQ:RAVN), the leader in autonomous agriculture technology, announced today the purchase of a second OMNiPOWER™ platform by Haggerty AgRobotics. Raven’s driverless ag and precision technology deliver impactful solutions for local and enterprise farms as the agriculture industry’s labor shortages continue to grow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005181/en/
“Labor shortage concerns within our local growers have really elevated the need for more automation and robotics on the farm,” said Chuck Baresich, President of Haggerty AgRobotics.
Haggerty Creek Ltd., an establised company delivering grain and crop input needs for growers in Ontario, Canada, has been collaborating with Raven to solve industry challenges for over a decade. In 2020, Haggerty Creek Ltd. purchased its first OMNiPOWER and in 2021 purchased OMNiDRIVE to help farmers with operational challenges they face. The growing demand for driverless ag technology as an impactful solution for labor shortages pushed Baresich to launch Haggerty AgRobotics, a service focused entirely on autonomy, robotics and technology automation at the farm level.
The second OMNiPOWER platform will allow Haggerty AgRobotics to lead the industry as one of the first customers to implement a real-world fleet of autonomous machines. Baresich will now manage a fleet of OMNi platforms with machine-to-machine connectivity through the Viper® 4+ field computer. The integration of Raven’s advanced precision farming technology within the OMNiPOWER platform allows for a seamless user experience and real-time shared coverage visibility.
“As one of the first customers of this technology, we are very excited to bring Raven driverless ag solutions to the market in a big way,” said Baresich. “The recent updates and advancements to Raven’s technology are impressive and we have experienced incredible performance in our 2021 spring program. We purchased our second OMNiPOWER platform to continue to be on the leading edge of commercializing autonomous machines as an organized fleet.”
“Raven has made significant investments in our OMNi suite of driverless ag solutions,” said Ben Voss, Raven Applied Technology Director of Sales for North America and Australia. “It is exciting to see a progressive, ag-tech focused operation like Haggerty AgRobotics partner with us to showcase autonomy and precision applications in the agriculture market. OMNiPOWER and OMNiDRIVE position both of us as autonomy pioneers in the global agriculture industry.”
Raven unveiled their OMNi brand of autonomous solutions less than a month ago and is actively fulfilling orders for both OMNiPOWER and OMNiDRIVE™ units worldwide. OMNiPOWER™ is a self-propelled power platform that easily interchanges farm implements like a sprayer or spreader. This autonomous platform empowers ag professionals to perform multiple farm tasks simultaneously without a driver. Raven’s Path to Autonomy begins with precision farming products that reduce driver fatigue and graduates up to full driverless ag technology automation.
By investing in driverless ag technology, Raven continues to design solutions that reduce operating costs, decrease inputs, and improve yields for ag professionals around the world. Available to order today at RavenPrecision.com .
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) is dedicated to providing innovative, high-value products and solutions that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and lighter-than-air technologies. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, high performance, and unmatched service. For more information, visit https://ravenind.com .
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite, Raven Autonomy™, is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com .
About Haggerty Creek Ltd.
Haggerty Creek Ltd. was established in 2001 to fill a market need in Ontario’s four counties area, being Lambdon, Middlesex, Elgin and Kent counties. Located north of Bothwell, Ontario, Haggerty Creek provides whole farm solutions, starting with precision crop planning and application, and ending with grain handling and marketing. In response to the growing demand for driverless ag technology, the company launched Haggerty AgRobotics, positioning themselves as a pioneer in a growing industry. Learn more at https://haggertycreek.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005181/en/
Link:
Social Media:
https://www.facebook.com/ravenprecision/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom